Neurocrine Biosciences, Inc. (NBIX)

Market Cap	12.03B
Revenue (ttm)	2.36B
Net Income (ttm)	341.30M
Shares Out	99.70M
EPS (ttm)	3.29
PE Ratio	36.68
Forward PE	18.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,894,340
Open	121.05
Previous Close	116.11
Day's Range	118.57 - 122.37
52-Week Range	110.95 - 157.98
Beta	0.33
Analysts	Buy
Price Target	168.35 (+39.49%)
Earnings Date	Feb 6, 2025

About NBIX

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 23, 1996
• Employees: 1,800
• Stock Exchange: NASDAQ
• Ticker Symbol: NBIX
• Website: https://www.neurocrine.com

Financial Performance

In 2024, Neurocrine Biosciences's revenue was $2.36 billion, an increase of 24.81% compared to the previous year's $1.89 billion. Earnings were $341.30 million, an increase of 36.68%.

Analyst Forecast

According to 21 analysts, the average rating for NBIX stock is "Buy." The 12-month stock price forecast is $168.35, which is an increase of 39.49% from the latest price.

Price Target

$168.35

(39.49% upside)

Analyst Consensus: Buy